
KBP pioneers in drug development, focusing on lung, heart, kidney diseases, and immunology, leveraging unique insights for innovative therapies.
Founded with a mission to innovate patient care, KBP Biosciences focuses on drug development for lung, heart, kidney diseases, and immunology. The company leverages its experienced discovery team to identify new compounds and maintains a deep pipeline of clinical and pre-clinical candidates. By integrating discovery and development efforts, KBP aims to delay disease progression and improve patient outcomes through its specialized research on major organ systems.
Notable figures associated with KBP Biosciences include experienced leaders in pharmacology and drug development. The company has achieved significant milestones, including the advancement of multiple compounds into clinical trials. KBP's impact is marked by its commitment to addressing critical health challenges and its contributions to the global pharmaceutical landscape through innovative therapies.

Knopp Biosciences
knoppbio.com

Know Bio
knowbiollc.com

KBI Biopharma

KPI Therapeutics

Kathera Bioscience
katherabio.com

Walden Biosciences

Kinaset Therapeutics
kinasettx.com

BridGene Biosciences

Bond Biosciences
bond.bio

KinDex Pharmaceuticals

Kiniksa Pharmaceuticals
kiniksa.com
Lung Biotechnology
unither.com

KBS Research
kbsresearch.com

BioKier
biokier.com
Kalypsys
kalypsys.com
Companies similar to KBP Biosciences include Knopp Biosciences, Know Bio, KBI Biopharma and KPI Therapeutics.
KBP Biosciences was founded in 2007.
KBP Biosciences' headquarters is located in Princeton, NJ, US.
KBP Biosciences' most recent funding round was for $76M (USD) in January 2018.
As of Jan 5, 2018, KBP Biosciences has raised a total of $76M (USD).
KBP Biosciences has 51 employees as of Feb 5, 2024.